{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-023362","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.566045+00:00","generated_at":"2026-05-18T23:55:46.805724+00:00","sec_items":["3.03","5.07","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BridgeBio stockholders approve officer exculpation amendment and 5M-share increase in stock plan","bullets":["Stockholders elected all five Class III director nominees: Kumar, Homcy, Dachille, Daniels, Lo.","Approved amendment to increase shares reserved under 2021 Stock Plan by 5,000,000 shares (128.9M for, 26.7M against).","Approved officer exculpation amendment to limit liability of certain officers as permitted under Delaware law (151.2M for, 5.6M against).","Ratified Deloitte & Touche as independent auditor for FY2025 (173.8M for, 56k against).","Non-binding advisory vote on executive compensation passed (117.6M for, 37.9M against, 1.2M abstain)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-023362","json":"https://secwatch.observer/filing/0001140361-25-023362.json","markdown":"https://secwatch.observer/filing/0001140361-25-023362.md","text":"https://secwatch.observer/filing/0001140361-25-023362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036125023362/0001140361-25-023362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036125023362/ny20050862x1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:55:46.805724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22e90ab34474dcf60f9b49164cf036f44337c5e5","claim":"BridgeBio Pharma, Inc.: Amendment to Certificate of Incorporation to include an officer exculpation provision limiting liability of certain officers as permitted by Delaware law (effective 2025-06-23).","evidence_excerpt":"an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time (the “Certificate of Incorporation”) to limit the liability of certain officers of the Company as permitted under current Delaware law (the “Officer Exculpation Amendment”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036125023362/0001140361-25-023362-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-23"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}